Abstract:Triple-negative breast cancer (TNBC) is the most aggressive, high recurrence and metastatic breast cancer subtype. There are few safe and effective therapeutic drugs for treatment of TNBC. The marine natural product MHO7 has been determined to be a potential antitumor agent. However, its moderate activity and complex structure hampered its clinical application. In this study, a series of novel derivatives with modification on C24 of MHO7 were first synthesized. Some of the analogues were significantly more potent than MHO7 against all selected breast cancer cell lines. Among them, compound 4m had the best activity, and its IC50 value against TNBC was up to 0.51 mM. A whole-genome transcriptomic analysis shown that the mechanism of compound 4m against TNBC cells was similar with that of parent com-pound MHO7. Subsequent cellular mechanism studies showed that compound 4m could induce apoptosis of MDA-MB-231 cells through mitochondria pathway and cause G1 phase arrest. Moreover, 4m could disrupt the expressions of MAPK/Akt pathway-associated proteins (p-p38 and p-Akt) and remarkably increase the ratio of Bax to Bcl-2 and activate cleaved caspase 3/9/PARP. Importantly, 4m could influence the expression of Smad 7, and p-Smad 3 to inhibit TNBC cells metastasis. Stability assays in rat plasma and liver microsomes indicated that 4m still have room for further optimization. And the results of the online molinspiration software predicted that 4m has desirable physicochemical properties but some properties still have violation from the Lipinski rule of five. Overall, the modification on C24 of MHO7 was a promising way for developing novel anti-TNBC agents with considerable potential for optimization. (C)& nbsp;2022 Published by Elsevier Masson SAS.

Design, Synthesis and Structure-Activity Relationship Studies of a Focused Library of Pyrimidine Moiety with Anti-Proliferative and Anti-Metastasis Activities in Triple Negative Breast Cancer.

Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer

Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives As A New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer

3D-QSAR, molecular docking, and new compound design of pyrimidine derivatives as Src small molecule inhibitors

Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2h,4h)-dione Analogues: Development of Potent Eef2k Degraders Against Triple-Negative Breast Cancer.

Synthesis and Structure-Activity Relationship Studies of Parthenolide Derivatives As Potential Anti-Triple Negative Breast Cancer Agents

Identification and Optimization of 3-Bromo-n'-(4-hydroxybenzylidene)-4-methylbenzohydrazide Derivatives As Mtor Inhibitors That Induce Autophagic Cell Death and Apoptosis in Triple-Negative Breast Cancer.

Synthesis and structure-activity relationship study of a potent MHO7 analogue as potential anti-triple negative breast cancer agent

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H,4 H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer

Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.

Design, Synthesis and Biological Evaluation of Anilide (dicarboxylic Acid) Shikonin Esters As Antitumor Agents Through Targeting PI3K/Akt/mTOR Signaling Pathway

Integrated Virtual Screening and Molecular Dynamics Simulation Approaches Revealed Potential Natural Inhibitors for DNMT1 As Therapeutic Solution for Triple Negative Breast Cancer.

Synthesis and biological evaluation of chromone derivatives against triple-negative breast cancer cells

Design, Synthesis, and Biological Evaluation of Novel 4,4′-Bipyridine Derivatives Acting As CDK9-Cyclin T1 Protein-Protein Interaction Inhibitors Against Triple-Negative Breast Cancer

Design, synthesis and biological evaluation of novel tetrahydrothieno [2,3-c]pyridine substitued benzoyl thiourea derivatives as PAK1 inhibitors in triple negative breast cancer

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives As Agents for the Treatment of Triple Negative Breast Cancer

Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea Derivatives Against Breast Cancer by Inhibiting PI3K/Akt/mTOR and Hedgehog Signalings

Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.

Design, Synthesis and Antitumor Activity of Novel Thiophene- Triazine Derivatives Bearing Arylurea Unit As Potent PI3K/mTOR Inhibitorss.

Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment